<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Czech and Slovak Ophthalmology</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">556</article-id>
      <article-categories>
        <subj-group>
          <subject>Original article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Application of Dysport® - the Possibilities of the Side Effect on the Eyelids Position (a Clinical – Histological study)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Krásný</surname>
            <given-names>Jan</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0341-0094</contrib-id>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Šach</surname>
            <given-names>Josef</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9287-7915</contrib-id>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="electronic">
        <day>22</day>
        <month>10</month>
        <year>2012</year>
      </pub-date>
      <issue>5</issue>
      <elocation-id>7</elocation-id>
      <abstract>
        <p>Aim: To inform about the possibility of negative influence of repeated application of the botulotoxine A derivate on the eye lid position with the changes of their tissue structure. At the same moment, the authors report on literature analysis of positive and negative influence of this neuro toxine from the medical point of view. Materials and methods: At the Department of Ophthalmology in the Faculty Hospital Královské Vinohrady, Prague, Czech Republic, E.U., there were surgically treated three patients after repeated applications of botulotoxine A derivates. The first case was bilateral ptosis of upper eyelids; the other two were indicated because of entropium with trichiasis of lower eyelids. In the medical history, there was recorded ten years lasting above-mentioned drug treatment for blepharospasm diagnosis in a 65 years old man introducing bilateral symmetrical ptosis. Because of the following frontal muscle involvement, and partial decreasing levator palpebrae muscles function, the positioning of the upper eyelids was treated by the aponeurosis plasty with good functional result. In two female patients, aged 72 and 90 years, the indication for successful surgical treatment was chronic entropium of lower eyelids; initially ineffectively treated by means of repeated intradermal injections of botulotoxin A derivates. Results: Histological examinations of the excided skin and subcutis samples taken during ectropium plasties showed unfavorable and irreversible changes including especially scarring of the eyelid and atrophy of the striated muscles. Conclusion: The indication of botulotoxine A derivates application should be carefully weighted and the proper indication should be chosen. From the ophthalmologic point of view, blefarospasmus only is the appropriate diagnosis, and the relative indication is the temporary induced ptosis of the upper eyelid closing the interpalpebral fissure to prevent corneal changes in lagophthalmos of various etiologies as an alternative to the tarsoraphy. Always we have to consider the frequency of applications, because repeatedly used derivate of this neurotoxine causes irreversible changes in cutaneous and subcutaneous tissue.</p>
      </abstract>
      <kwd-group>
        <kwd>Botulotoxine A</kwd>
        <kwd>entropium</kwd>
        <kwd>histology</kwd>
        <kwd>ptosis</kwd>
        <kwd>treatment side effect</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R12540">
        <mixed-citation>Brin, M.F., Boodhoo, TI, et. al.: Safety and tolerability of onabo- tulinumtoxin A in the treatment of facial lines: a meta-analysis of in- dividual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol, 61; 2009: 961–970.</mixed-citation>
      </ref>
      <ref id="R12541">
        <mixed-citation>Choi, J.C., Lucarelli, M.J., Shore, J.V.V.: Use of botulinum toxin A in pacients at risk of wound compli- cations following eyelid reconstruc- tion. Ophthal Plast Reconstr Surg, 13; 1997: 259–264.</mixed-citation>
      </ref>
      <ref id="R12542">
        <mixed-citation>Clark, G.T.: The management of oromandibular motor disorders and facial spasm with injections of botu- linum toxin. Phys Med Rehabil Clin N Am, 14; 2003: 727–748.</mixed-citation>
      </ref>
      <ref id="R12543">
        <mixed-citation>Costa, P.G., Saraiva, F.P., et al.: Comparative study of Botox in- jection treatment for upper eyelid retraction with 6-moth follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye, 223; 2009: 767–773.</mixed-citation>
      </ref>
      <ref id="R12544">
        <mixed-citation>Crouch, E.R.: Use of botulinum to- xin in strabismus., Curr Opin Oph- thalmol, 17; 2006: 435–440.</mixed-citation>
      </ref>
      <ref id="R12545">
        <mixed-citation>Dressler, D., Wohlfahrt, K., et al.: Antibody-induced failure of botuli- num toxin a therapy in cosmetic in- dication. Dermatol Surg, 36; 2010, Suppl. 4: 2182–2187.</mixed-citation>
      </ref>
      <ref id="R12546">
        <mixed-citation>Eston, J.S., Russel, B.W.: Effect of treatment with botulinum toxin on neurogenic blepharospasm. Brit Med J, 290; 1985: 1857–1859.</mixed-citation>
      </ref>
      <ref id="R12547">
        <mixed-citation>Gedrange, T., Gredes, T., et al.: Histological changes and changes in the myosin mRNA content of the porcine masticatory muscles af- ter masseter treatment botulinum toxin A. Clin Oral Investig, 2012, Springer, (v předstihu publikováno na PubMed).</mixed-citation>
      </ref>
      <ref id="R12548">
        <mixed-citation>Gerinec, A., Slyško, P., Fišerová, O.: Prinos botulotoxínu v liečbě strabizmu. Čes a Slov Oftal, 54; 1998: 174–178.</mixed-citation>
      </ref>
      <ref id="R12549">
        <mixed-citation>Grandas, F., Elston, J., et al.: Ble- pharospasm: a review of 264 pati- ents. J Nerol Neurosurg Psychiat, 51; 1988: 767–772.</mixed-citation>
      </ref>
      <ref id="R12550">
        <mixed-citation>Gumus, K., Lee, S., et al.: Botulinum toxin injection for the management of refractory filamentary keratitis. Arch Ophthalmol, 130; 2012: 446–450.</mixed-citation>
      </ref>
      <ref id="R12551">
        <mixed-citation>Hayton, MJ., Dantini, A.J., et al.: Botulinum toxin injection in the treatment of tennis elbow. A double- -blind, randomized, controlled, pilot study. J Bone Joint Surg Am, 87; 2005: 503–507.</mixed-citation>
      </ref>
      <ref id="R12552">
        <mixed-citation>Klein, A.V.V.: Botox for the eyes and eyebrows. Dermatol Slin, 22; 2004: 145–149.</mixed-citation>
      </ref>
      <ref id="R12553">
        <mixed-citation>Kowal, L., Wong, E., Yahalon, C.: Botulinum toxin in the treatment of strabismus. A review of its use and effects. Disdabil Rehabil, 23; 2007: 1823–1831.</mixed-citation>
      </ref>
      <ref id="R12554">
        <mixed-citation>Lueder, G.T., Galli, M., et al.: Longterm reset of botulinum toxin-augmended medial rectus recessions for largeangle infantile esotropia. Am J Ophthalmol, 153; 2012: 560–563.</mixed-citation>
      </ref>
      <ref id="R12555">
        <mixed-citation>Naik, M.N., Gangopadhyay, N., et al.: Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection. Eye, 22; 2008: 1132–1136.</mixed-citation>
      </ref>
      <ref id="R12556">
        <mixed-citation>Niautu, J. 3rd: Complications in Fillers and Botox. Oral. Maxillofac. Surg Clin North A, 21; 2009: 13–21.</mixed-citation>
      </ref>
      <ref id="R12557">
        <mixed-citation>Niautu, J. 3rd.: Botulin toxin A: a review of 1.085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg, 61; 2003: 317–324.</mixed-citation>
      </ref>
      <ref id="R12558">
        <mixed-citation>Otradovec, J.: Klinická neurooftalmologie, Grada, Praha, 2003, s.</mixed-citation>
      </ref>
      <ref id="R12559">
        <mixed-citation>Paloma, V., Samper, A.: A complication with the aesthetic use a Botox: Herniation of the orbital fat. Plast Reconstr Surg, 107; 2001: 1315.</mixed-citation>
      </ref>
      <ref id="R12560">
        <mixed-citation>Pagen, F.L., Harrison, A.: A guide to dosing in the treatment of cervical dystonia and blepharospasm with XeominR: new botulin neurotoxin A. Parkinsonism Relat. Disord., 18, 2012: 441–445.</mixed-citation>
      </ref>
      <ref id="R12561">
        <mixed-citation>Prado, A., Fuentes, P., et al.: Pseudoaneurysm of the frontal branch of the superfacial temporal artery: an unusual complication after the injection of Botox. Plast. Reconstr. Surg., 119, 2007: 2334–2335.</mixed-citation>
      </ref>
      <ref id="R12562">
        <mixed-citation>Prager, W., Huber-Vorländer, J., Taufig, A,Z.. et al.: Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol, 5; 2012: 53–56.</mixed-citation>
      </ref>
      <ref id="R12563">
        <mixed-citation>Reddy, U.P., Woodward, J.A.: Abobotulinum toxin A (Dysport) and botulinum toxin type A (Botox) for purposeful induction of eyelid ptosis. Ophthal Plast Reconstr Surg, 26; 2010: 489–491.</mixed-citation>
      </ref>
      <ref id="R12564">
        <mixed-citation>Remeš, F., Roth, J., Růžička, E.: Léčebné použití Botulotoxinu v neurologii. Prakt Lék, 74; 1994: 174–177.</mixed-citation>
      </ref>
      <ref id="R12565">
        <mixed-citation>Roehm, P.C., Perry, J.D. et al.: Prevalence of periocular depigmentation after repeated botulin toxin A injections in African American patients. J Neroophthalmol, 19; 1999: 7–9.</mixed-citation>
      </ref>
      <ref id="R12566">
        <mixed-citation>Rousseaux, M., Buisset, N., et al.: Comparison of botulinum toxin injection and nerotomy in patiens with distal lower limb spasticity. Eu J Neurol, 15, 2008: 506–511.</mixed-citation>
      </ref>
      <ref id="R12567">
        <mixed-citation>Rowe, F.J., Noonan, C.P.: Botulin toxin for the treatment of strabismus. Cochrane Database Syst. Rev., 2012, Ef. 15:2: CD006499.</mixed-citation>
      </ref>
      <ref id="R12568">
        <mixed-citation>Růžička, E., Roth, J., Diblík, P.: Botulotoxin v léčbě blefarospazmu. Čas Lék čes, 131; 1992: 213–216.</mixed-citation>
      </ref>
      <ref id="R12569">
        <mixed-citation>Scott, AB.: Botulinum toxin injections into extra-ocular muscles as an alternative to strabismus surgery. Ophthalmology, 87; 1980: 1044–1049.</mixed-citation>
      </ref>
      <ref id="R12570">
        <mixed-citation>Scott, A.B., Kennedy, R.A., Stubbs, H.A.: Botulinum toxin injection as treatment for blefarospasm., Arch. Ophthalmol., 103; 1985: 347–350.</mixed-citation>
      </ref>
      <ref id="R12571">
        <mixed-citation>Vácha, J., Bodnár, M., et al.: Botulotoxín A – jedna z možností léčby strabismu. Folia Strabol Neuroophtalmol, 6; 2003, Suppl. 1.: 50–51.</mixed-citation>
      </ref>
      <ref id="R12572">
        <mixed-citation>Vartanian, A.J., Davan, S., H.: Complications of botulinum toxin A use in facial rejuvenation., Facial. Plast. Surg. Clin North Am, 11; 2003: 483–492.</mixed-citation>
      </ref>
      <ref id="R12573">
        <mixed-citation>Wabbels, B., Reichel, G., Fulford- -Smith, A. et al.: Double-blind, randomized, parallel group pilot study comparing two botulinum toxin type A products for treatment of blepharospasm. J Neural Trans, 118; 2011: 233–239.</mixed-citation>
      </ref>
      <ref id="R12574">
        <mixed-citation>Winner, P.K., Sadowsky, C.H. et al.: Concurrent Onabotulinum toxin A treatment of cervical dystonia and concomitant migrace. Haedache, 18; 2012: 15 - 26.</mixed-citation>
      </ref>
      <ref id="R12575">
        <mixed-citation>Wojno, T.H.: Results of lacrimal gland botulinum toxin injection for epifora in lacrimal obstruction and gustatory tearing. Ophthal Plast Reconstr Surg, 27; 2011: 119–121.</mixed-citation>
      </ref>
      <ref id="R12576">
        <mixed-citation>Yoon, J.S., Kim, J.C., Lee, S.Y.: Double-blind, randomized, comparative study of Medoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol, 23; 2009:137–141.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
